TOCAINIDE

TOCAINIDE 속성

TOCAINIDE C화학적 특성, 용도, 생산

용도

Tocainide is used for suppressing symptoms of ventricular arrhythmia and tachycardia, and for premature cardiac contractions.

정의

ChEBI: A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.

World Health Organization (WHO)

Tocainide, an antidysrhythmic agent, was introduced in 1981 for the treatment of ventricular dysrhythmias. By 1984 its use was associated with cases of agranulocytosis, aplastic anaemia and thrombocytopenia, some of which were fatal. This led some regulatory authorities to restrict the indications for its use. The major manufacturer has subsequently restricted its use on a worldwide basis to the treatment of symptomatic ventricular dysrhythmias not responding to other therapy, or when other therapy is contraindicated.

Pharmacokinetics

The α-methyl group is believed to slow the rate of metabolism and, thereby, to contribute to oral activity. The plasma half-life of tocainide is approximately 12 hours, and nearly 50% of the drug may be excreted unchanged in the urine. Adverse effects associated with tocainide are like those observed with lidocaine—specifically, gastrointestinal disturbances and central nervous system effects.

Clinical Use

Tocainide (Tonocard) is an orally effective antiarrhythmic agent with close structural similarities to lidocaine. Tocainide is indicated for the treatment of symptomatic ventricular arrhythmias refractory to more conventional therapy. Serious noncardiac adverse effects limit its use to patients with life-threatening arrhythmias.

부작용

Light-headedness, dizziness, or nausea occurs in approximately 15% of patients, paresthesias and numbness in 9%, and tremor in 8%.These adverse effects are generally mild in intensity, transient, and dose related. Overall, however, approximately 20% of patients prescribed tocainide discontinue therapy because of such effects. Serious immune-based side effects, such as pulmonary fibrosis, have been reported, and blood dyscrasias, such as agranulocytosis and thrombocytopenia, may occur in up to 0.2% of patients.

Drug interactions

When used with other class IB antiarrhythmic drugs, tocainide toxicity may be increased without significant gain in antiarrhythmic efficacy.

주의 사항

Patients who are hypersensitive to tocainide or to local anesthetics of the amide type should not be exposed to tocainide.The presence of second- or third-degree heart block in the absence of an artificial pacemaker also contraindicates the use of tocainide.

TOCAINIDE 준비 용품 및 원자재

원자재

준비 용품

TOCAINIDE 공급 업체

공급자	전화	이메일	국가	제품 수	이점
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32715	60
Hubei Jusheng Technology Co.,Ltd.	18871490254	linda@hubeijusheng.com	CHINA	28180	58
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	19892	58
Wuxi Rejoys chemical Technology Co., Ltd.	0510-86103381	sales@rejoyschem.com	CHINA	976	58
Shaanxi Dideu Medichem Co. Ltd	+86-029-89586680 +86-18192503167	1026@dideu.com	China	9126	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	27537	58
ZHEJIANG JIUZHOU CHEM CO., LTD	+86-0576225566889 +86-13454675544	admin@jiuzhou-chem.com；jamie@jiuzhou-chem.com；alice@jiuzhou-chem.com	China	19949	58
Shanghai Acmec Biochemical Technology Co., Ltd.	+undefined18621343501	product@acmec-e.com	China	33350	58
Aladdin Scientific	+1-+1(833)-552-7181	sales@aladdinsci.com	United States	57511	58
Mainchem Co., Ltd.	+86-0592-6210733	sale@mainchem.com	China	32360	55

TOCAINIDE 관련 검색: